The first development candidate has been nominated under a collaboration between Carisma Therapeutics Inc. and Moderna Inc. to discover, develop and commercialize in vivo engineered chimeric antigen receptor monocytes and macrophages (CAR-M) therapeutics for the treatment of cancer.
Oncopeptides AB has selected its first candidate drug based on the company’s unique platform for small polypeptide-based innate killer engagers (SPiKE). The SPiKE platform uses multispecific constructs, able to bind to multiple targets simultaneously.
CAR T-cell therapy that targets BCMA is an effective option for treating relapsed/refractory multiple myeloma, but there is a lack of persistence due to the inability to develop a memory phenotype.
CSPC Pharmaceutical Group Ltd. has obtained clearance from China’s National Medical Products Administration (NMPA) to conduct clinical trials in China with the first mRNA-lipid nanoparticles (LNP)-based CAR T-cell injection, SYS-6020.
Defence Therapeutics Inc. has demonstrated that its second-generation ARM-X anticancer vaccine is therapeutically effective against pre-established ovarian cancer (ID8 model) when combined with an anti-PD-1 immune checkpoint inhibitor.
CDR-Life Inc. has expanded its pipeline of novel T-cell engagers (TCE) with the addition of CDR-813 and CDR-505. CDR-813 is a highly potent and selective TCE candidate targeting tumors expressing PRAME (preferentially expressed antigen in melanoma) in HLA-A*02:01 patients.
Adicet Bio Inc. has obtained FDA clearance of its IND application to evaluate ADI-270, an armored allogeneic λδ CAR T-cell therapy candidate targeting CD70-positive cancers, for the treatment of relapsed or refractory renal cell carcinoma (RCC).
Immutep Ltd. has signed a license agreement with Cardiff University granting the company exclusive rights to develop and commercialize anti-LAG-3 small molecules.
Medigene AG has selected its lead candidate for MDG-2021, a T-cell receptor engineered T-cell (TCR-T) therapy targeting KRAS G12D with human leukocyte antigen (HLA)-A*11 being developed in combination with the company’s PD1-41BB costimulatory switch protein (CSP) technology.
Scientists at Minghui Pharmaceutical (Hangzhou) Ltd. and Minghui Pharmaceutical Inc. have synthesized antibody-drug conjugates comprising a humanized monoclonal antibody targeting insulin-like growth factor 1 receptor (IGF-1R) linked to a cytotoxic drug through a linker and reported to be useful for the treatment of cancer.
RSS
